GLP-1 R3ta

Unlike compounds that target only one or two pathways, Reta** acts on three receptors — GLP-1, GIP, and glucagon. This triple-action approach may influence hunger and fullness signals, energy use, and metabolic function. Research areas include: • Appetite and satiety signaling • Metabolic function • Energy expenditure • Glucose regulation • Body-weight regulation Reta**is still under clinical investigation and has not been approved by the FDA for medical use. For research purposes only. Not for human consumption.

For laboratory research use only. Not for human consumption. Not for diagnostic or therapeutic use. Not evaluated by the FDA. By purchasing you agree to our Terms of Sale and Research Use Disclaimer.